AstraZeneca PLC (AZN)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

13,560.00p

Buy

13,564.00p

arrow-up358.00p (+2.71%)

Prices updated at 04 Jun 2026, 18:38 BST

Prices minimum 15 mins delay

Prices in GBX

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic ...

FTSE All-Share

0.29%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2024	2025
	54,073m	58,739m
	43,866m	48,106m
	10,251m	13,327m
	18.96	22.69
	7,035m	10,225m
	15,438m	19,506m
Sales, General and administrative	20,224m	20,774m
Interest expenses	1,682m	1,614m
Provision for income taxes	1,650m	2,169m
Operating expenses	33,615m	34,779m
Income before taxes	8,691m	12,402m
Net income available to common shareholders	7,035m	10,225m
	4.54	6.6
Net interest income	-1,337m	-1,254m
Advertising and promotion	-	-
Net investment income, net	-42m	-31m
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	4.5	6.54
Free cash flow per share	3.4442	4.5477
Book value/share	20.9346	21.9747
Debt equity ratio	0.677169	0.537037

Balance sheet

Year chevron-l-regular chevron-r-regular	2024	2025
Current assets	25,827m	28,723m
Current liabilities	27,866m	30,617m
Total capital	67,292m	73,382m
Total debt	30,114m	29,149m
Total equity	40,786m	48,667m
Total non current liabilities	-	-
Loans	26,506m	24,715m
Total assets	104,035m	114,074m
Total liabilities	-	-
Cash and cash equivalents	5,488m	5,711m
Common stock	1,550m	1,551m

Cash flow

Year chevron-l-regular chevron-r-regular	2024	2025
Cash at beginning of period	5,637m	5,429m
Cash dividends paid	-4,629m	-4,971m
	7,275m	8,670m
Investments (gains) losses	-7,980m	-6,808m
	5,429m	5,698m
Net income	-	-
	11,861m	14,575m
	-4,586m	-5,905m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.